Ingredients by Nature receives patent approval for use of eriocitrin to support blood glucose
The U.S. Patent and Trademark Office has approved a patent for the use of eriocitrin in Ingredient By Nature’s ingredient formulations, such as Eriomin, a citrus flavonoid designed for blood glucose support.
Photo © iStockphoto.com/eli_asenova
The U.S. Patent and Trademark Office has approved a patent for the use of eriocitrin in Ingredient By Nature’s (IBN; Montclair, CA) ingredient formulations, such as Eriomin, a citrus flavonoid designed for blood glucose support. The specific patent claim states that eriocitrin can be used as, “A method of reducing blood glucose levels in a human subject in need thereof, comprising administering to the subject a composition comprising 100-200 mg eriocitrin once per day.”
“We couldn’t be happier with the progress we have made to recognize eriocitrin as a viable option for better health,” said Rob Brewster, president of IBN, in a press release. “Supported by a successful first clinical trial and now this patent, our line of Eriomin lemon flavonoid blends, which are primarily comprised of eriocitrin, provide powerful support to managing healthy blood glucose levels. We look forward to revealing additional significant results from ongoing research into the effect that eriocitrin can have on blood glucose levels later this year.”
HHS announces restructuring plans to consolidate divisions and downsize workforce
Published: March 27th 2025 | Updated: March 27th 2025According to the announcement, the restructuring will save taxpayers $1.8 billion per year by reducing the workforce by 10,000 full-time employees and consolidating the department’s 28 divisions into 15 new divisions.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
